Format

Send to

Choose Destination
Front Immunol. 2018 Feb 7;9:199. doi: 10.3389/fimmu.2018.00199. eCollection 2018.

CD137+CD154- Expression As a Regulatory T Cell (Treg)-Specific Activation Signature for Identification and Sorting of Stable Human Tregs from In Vitro Expansion Cultures.

Author information

1
German Rheumatism Research Centre (DRFZ) Berlin, Leibniz Association, Berlin, Germany.
2
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany.
3
Department of Cellular Immunology, Clinic for Rheumatology and Clinical Immunology, Charité - University Medicine, Berlin, Germany.
4
Institute for Medical Immunology, Charité - University Medicine, Berlin, Germany.
5
Department of Genetics/Epigenetics, Saarland University, Saarbrücken, Germany.
6
Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité - University Medicine, Berlin, Germany.

Abstract

Regulatory T cells (Tregs) are an attractive therapeutic tool for several different immune pathologies. Therapeutic Treg application often requires prolonged in vitro culture to generate sufficient Treg numbers or to optimize their functionality, e.g., via genetic engineering of their antigen receptors. However, purity of clinical Treg expansion cultures is highly variable, and currently, it is impossible to identify and separate stable Tregs from contaminating effector T cells, either ex vivo or after prior expansion. This represents a major obstacle for quality assurance of expanded Tregs and raises significant safety concerns. Here, we describe a Treg activation signature that allows identification and sorting of epigenetically imprinted Tregs even after prolonged in vitro culture. We show that short-term reactivation resulted in expression of CD137 but not CD154 on stable FoxP3+ Tregs that displayed a demethylated Treg-specific demethylated region, high suppressive potential, and lack of inflammatory cytokine expression. We also applied this Treg activation signature for rapid testing of chimeric antigen receptor functionality in human Tregs and identified major differences in the signaling requirements regarding CD137 versus CD28 costimulation. Taken together, CD137+CD154- expression emerges as a universal Treg activation signature ex vivo and upon in vitro expansion allowing the identification and isolation of epigenetically stable antigen-activated Tregs and providing a means for their rapid functional testing in vitro.

KEYWORDS:

CD137; adoptive regulatory T cell therapy; chimeric antigen receptor; regulatory T cell expansion; regulatory T cell signaling; regulatory T cell stability; regulatory T cells

PMID:
29467769
PMCID:
PMC5808295
DOI:
10.3389/fimmu.2018.00199
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center